重組疫苗市場規模、佔有率及成長分析（按類型、疾病、最終用戶、分銷管道和地區）- 2025-2032 年產業預測

重組疫苗市場預計在 2023 年價值為 100.5 億美元，並從 2024 年的 112 億美元成長到 2032 年的 265.5 億美元，預測期內（2025-2032 年）的複合年成長率為 11.4%。

截至 2023 年 10 月，由於基因工程、基因組學和重組 DNA 技術的進步，疫苗市場正在變革時期。傳統疫苗主要依賴病原體減毒或惰性暴露策略，正逐漸被實驗室開發的創新替代方案所取代。這些新疫苗利用基因篩檢技術有效消除與感染疾病相關的風險，提高了疫苗接種過程的有效性和安全性。這一演變標誌著免疫接種的關鍵時刻，提供了更精準、更有針對性的方法來改善公共衛生結果。將最尖端科技融入疫苗研發，不僅將拓寬市場前景，也將為醫療保健領域的疫苗接種實踐樹立新的標準。

目錄

介紹

• 調查目的
• 研究範圍
• 定義

調查方法

• 資訊採購
• 次要和主要資料方法
• 市場規模預測
• 市場假設與限制

執行摘要

• 全球市場展望
• 供需趨勢分析
• 細分機會分析

市場動態及展望

• 市場概況
• 市場規模
• 市場動態
  • 促進因素和機會
  • 限制與挑戰
• 波特的分析

主要市場考察

• 關鍵成功因素
• 競爭程度
• 主要投資機會
• 市場生態系統
• 市場吸引力指數（2024 年）
• PESTEL 分析
• 宏觀經濟指標
• 價值鏈分析
• 定價分析

重組疫苗市場規模（按類型）

• 市場概況
• 次單元重組疫苗
• 減毒重組疫苗
• 載體重組疫苗

重組疫苗市場規模（按疾病）

• 市場概況
• 肺炎鏈球菌感染
• 癌症
• B型肝炎
• 流感
• 二氧化矽
• 其他

重組疫苗市場規模（以最終用戶分類）

• 市場概況
• 孩子們
• 成人
• 老年人

重組疫苗市場規模（依分銷管道分類）

• 市場概況
• 醫院和藥房
• 政府供應商

重組疫苗市場規模

• 北美洲
  • 美國
  • 加拿大
• 歐洲
  • 德國
  • 西班牙
  • 法國
  • 英國
  • 義大利
  • 其他歐洲國家地區
• 亞太地區
  • 中國
  • 印度
  • 日本
  • 韓國
  • 其他亞太地區
• 拉丁美洲
  • 巴西
  • 其他拉丁美洲國家
• 中東和非洲
  • 海灣合作理事會國家
  • 南非
  • 其他中東和非洲地區

競爭資訊

• 前 5 家公司對比
• 主要企業市場定位（2024年）
• 主要市場參與者所採用的策略
• 近期市場趨勢
• 公司市場佔有率分析（2024 年）
• 主要企業簡介
  • 公司詳細資訊
  • 產品系列分析
  • 公司分部佔有率分析
  • 收益與前一年同期比較對比（2022-2024 年）

主要企業簡介

• Pfizer Inc.（United States）
• GlaxoSmithKline plc（GSK）（United Kingdom）
• Merck & Co., Inc.（United States）
• Moderna, Inc.（United States）
• Novavax, Inc.（United States）
• Johnson & Johnson（United States）
• AstraZeneca plc（United Kingdom）
• Bavarian Nordic A/S（Denmark）
• BioNTech SE（Germany）
• Vaxart, Inc.（United States）
• Transgene SA（France）
• GeoVax Labs, Inc.（United States）
• Vaxcyte, Inc.（United States）
• Green Cross Corporation（GC Biopharma）（South Korea）
• Bharat Biotech International Limited（India）
• Shantha Biotechnics Limited（India）
• Valneva SE（France）
• Inovio Pharmaceuticals, Inc.（United States）
• Sinovac Biotech Ltd.（China）

結論和建議

Recombinant Vaccines Market size was valued at USD 10.05 billion in 2023 and is poised to grow from USD 11.2 billion in 2024 to USD 26.55 billion by 2032, growing at a CAGR of 11.4% during the forecast period (2025-2032).

As of October 2023, the vaccine market is undergoing a transformative shift driven by advancements in genetic engineering, genomics, and recombinant DNA technologies. Traditional vaccines, which primarily utilized exposure strategies through pathogen attenuation or inactivation, are gradually giving way to innovative laboratory-developed alternatives. These new vaccines harness genetic screening techniques to effectively remove the risks associated with infectious diseases, ensuring both efficacy and heightened safety in vaccination processes. This evolution signifies a pivotal moment in immunization, offering a more precise and targeted approach that enhances public health outcomes. The integration of cutting-edge technology into vaccine development not only broadens the market landscape but also sets new standards for immunization practices in the healthcare sector.

Top-down and bottom-up approaches were used to estimate and validate the size of the Recombinant Vaccines market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Recombinant Vaccines Market Segments Analysis

Global Recombinant Vaccines Market is segmented by Type, Disease, End User, Distribution Channel and region. Based on Type, the market is segmented into Subunit recombinant vaccines, Attenuated recombinant vaccines and Vector recombinant vaccines. Based on Disease, the market is segmented into Pneumococcal Disease, Cancer, Hepatitis B, Influenza, DPT and Others. Based on End User, the market is segmented into Pediatric, Adult and Geriatric. Based on Distribution Channel, the market is segmented into Hospital & Retail Pharmacies and Government Suppliers. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Recombinant Vaccines Market

A key driver of growth in the recombinant vaccines market is the widespread use of recombinant technology, which significantly boosts both the effectiveness and safety of vaccines given to patients. This technology allows for the swift and large-scale production of vaccines, reducing the chances of supply shortages. Additionally, recombinant vaccines do not contain infectious viral particles, which decreases the risk of infection and makes them suitable for individuals with weakened immune systems. The advantages of these vaccines have prompted manufacturers to invest in the development of innovative solutions aimed at viral diseases, utilizing advanced DNA technology, genomics, and state-of-the-art biotechnology techniques to create safer and more effective vaccines.

Restraints in the Recombinant Vaccines Market

The growth of the recombinant vaccines market is hindered by multiple challenges, particularly the high cost associated with each dose, which poses a substantial barrier to widespread adoption. Although international organizations are actively working to enhance global vaccination efforts by distributing millions of doses in various regions, the steep price of these vaccines limits accessibility for numerous populations. As a result, despite ongoing initiatives aimed at ensuring equitable distribution, certain areas still struggle to overcome the financial obstacles tied to vaccination. This situation creates significant disparities in vaccine access, ultimately impacting public health outcomes across different demographics.

Market Trends of the Recombinant Vaccines Market

The Recombinant Vaccines market is witnessing significant growth driven by the rising prevalence of infectious diseases and the urgent need for effective immunization strategies, particularly for vulnerable populations such as the elderly and children. Efforts led by international organizations, including UNICEF and PAHO, to ensure the rapid distribution of vaccines in emergency situations have underscored the critical role of recombinant technologies in enhancing vaccine efficacy and accessibility. This trend not only reflects the global commitment to public health but also highlights advancements in vaccine development, which are pivotal in strengthening community immunity and curbing disease outbreaks worldwide.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2024
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis

Global Recombinant Vaccines Market Size by Type & CAGR (2025-2032)

• Market Overview
• Subunit recombinant vaccines
• Attenuated recombinant vaccines
• Vector recombinant vaccines

Global Recombinant Vaccines Market Size by Disease & CAGR (2025-2032)

• Market Overview
• Pneumococcal Disease
• Cancer
• Hepatitis B
• Influenza
• DPT
• Others

Global Recombinant Vaccines Market Size by End User & CAGR (2025-2032)

• Market Overview
• Pediatric
• Adult
• Geriatric

Global Recombinant Vaccines Market Size by Distribution Channel & CAGR (2025-2032)

• Market Overview
• Hospital & Retail Pharmacies
• Government Suppliers

Global Recombinant Vaccines Market Size & CAGR (2025-2032)

• North America (Type, Disease, End User, Distribution Channel)
  • US
  • Canada
• Europe (Type, Disease, End User, Distribution Channel)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Type, Disease, End User, Distribution Channel)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Type, Disease, End User, Distribution Channel)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Type, Disease, End User, Distribution Channel)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2024
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2024
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2022-2024)

Key Company Profiles

• Pfizer Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• GlaxoSmithKline plc (GSK) (United Kingdom)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Merck & Co., Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Moderna, Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Novavax, Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Johnson & Johnson (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AstraZeneca plc (United Kingdom)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bavarian Nordic A/S (Denmark)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• BioNTech SE (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Vaxart, Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Transgene S.A. (France)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• GeoVax Labs, Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Vaxcyte, Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Green Cross Corporation (GC Biopharma) (South Korea)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bharat Biotech International Limited (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Shantha Biotechnics Limited (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Valneva SE (France)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Inovio Pharmaceuticals, Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sinovac Biotech Ltd. (China)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations